Search the Community
Showing results for tags 'population control'.
Pfizer (+0.75%) is putting its consumer healthcare business on the trading block, either as a sale or spin-off. The drugmaker’s $3.4 billion unit features a medicine cabinet of popular productsyou’ll probably use at least once today, such as ChapStick, Centrum, and Advil. So what’s got Pfizer thinking about drug deals? Well, the $10 billion+ from a sale would give it ammo for a blockbuster acquisition(rumor on the street…it’s eyeing BMS). Plus, Pfizer is looking to zero in on its lucrative prescription drug business that has helped boost shares 7.5% YoY. This might be déjà vu all over again for Pfizer. It sold its consumer healthcare business to J&J back in 2006 for $16.6 billion only to buy another portfolio (which included Advil and ChapStick) when it acquired Wyeth in 2009. So why not write a script for one more? https://www.morningbrew.com/stories/doctors-orders/